CA2148455A1 - Composes nitrosoaromatiques lies a l'adenosine-diphosphoribose-polymerase, utiles comme agents anti-retroviraux et anti-tumeurs - Google Patents

Composes nitrosoaromatiques lies a l'adenosine-diphosphoribose-polymerase, utiles comme agents anti-retroviraux et anti-tumeurs

Info

Publication number: CA2148455A1
Authority: CA; Canada
Prior art keywords: nitroso; group; compound; nitrosobenzamide; isoquinolinone
Prior art date: 1992-11-02
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

CA002148455A

Other languages

English (en)

Inventor

Ernest Kun

Jerome Mendeleyev

William G. Rice

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Emory University

Octamer Inc

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1992-11-02

Filing date

1993-10-04

Publication date

1994-05-11

1992-11-02 Priority claimed from US07/965,541 external-priority patent/US5516941A/en

1993-10-04 Application filed by Individual filed Critical Individual

1994-05-11 Publication of CA2148455A1 publication Critical patent/CA2148455A1/fr

Status Abandoned legal-status Critical Current

Links

230000027455 binding Effects 0.000 title description 13
-1 nitroso aromatic compounds Chemical class 0.000 title description 9
239000002246 antineoplastic agent Substances 0.000 title description 7
229940124522 antiretrovirals Drugs 0.000 title description 3
239000003903 antiretrovirus agent Substances 0.000 title description 3
PWJFNRJRHXWEPT-AOOZFPJJSA-N [[(2r,3s,4r,5r)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2r,3r,4r)-2,3,4-trihydroxy-5-oxopentyl] hydrogen phosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OC[C@@H](O)[C@@H](O)[C@@H](O)C=O)[C@@H](O)[C@H]1O PWJFNRJRHXWEPT-AOOZFPJJSA-N 0.000 title description 2
OZUBORKYZRYLSQ-UHFFFAOYSA-N 3-nitrosobenzamide Chemical compound NC(=O)C1=CC=CC(N=O)=C1 OZUBORKYZRYLSQ-UHFFFAOYSA-N 0.000 claims abstract description 168
150000001875 compounds Chemical class 0.000 claims abstract description 120
238000000034 method Methods 0.000 claims abstract description 79
HXTDAUGEZTYMGP-UHFFFAOYSA-N 6-nitrosochromen-2-one Chemical compound O1C(=O)C=CC2=CC(N=O)=CC=C21 HXTDAUGEZTYMGP-UHFFFAOYSA-N 0.000 claims abstract description 62
241000700605 Viruses Species 0.000 claims abstract description 61
239000000203 mixture Substances 0.000 claims abstract description 48
208000015181 infectious disease Diseases 0.000 claims abstract description 22
206010028980 Neoplasm Diseases 0.000 claims abstract description 17
230000002458 infectious effect Effects 0.000 claims abstract description 12
OGNNAUZIERMVAR-UHFFFAOYSA-N 7-nitroso-2h-isoquinolin-1-one Chemical compound C1=CNC(=O)C2=CC(N=O)=CC=C21 OGNNAUZIERMVAR-UHFFFAOYSA-N 0.000 claims abstract description 11
201000011510 cancer Diseases 0.000 claims abstract description 11
ULPKKDKKGOEOPQ-UHFFFAOYSA-N 8-nitroso-2h-isoquinolin-1-one Chemical compound C1=CNC(=O)C2=C1C=CC=C2N=O ULPKKDKKGOEOPQ-UHFFFAOYSA-N 0.000 claims abstract description 10
230000000415 inactivating effect Effects 0.000 claims abstract description 9
LUMOXZOMRFGLRU-UHFFFAOYSA-N 5-nitroso-2h-isoquinolin-1-one Chemical compound C1=CNC(=O)C2=C1C(N=O)=CC=C2 LUMOXZOMRFGLRU-UHFFFAOYSA-N 0.000 claims abstract description 8
125000000018 nitroso group Chemical group N(=O)* 0.000 claims description 61
241000713772 Human immunodeficiency virus 1 Species 0.000 claims description 37
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 24
229910052739 hydrogen Inorganic materials 0.000 claims description 24
239000001257 hydrogen Substances 0.000 claims description 24
241000725303 Human immunodeficiency virus Species 0.000 claims description 16
241001430294 unidentified retrovirus Species 0.000 claims description 16
230000003612 virological effect Effects 0.000 claims description 16
239000012620 biological material Substances 0.000 claims description 15
150000002832 nitroso derivatives Chemical class 0.000 claims description 15
108090001074 Nucleocapsid Proteins Proteins 0.000 claims description 14
230000001177 retroviral effect Effects 0.000 claims description 14
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 10
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 9
PXBFMLJZNCDSMP-UHFFFAOYSA-N 2-Aminobenzamide Chemical compound NC(=O)C1=CC=CC=C1N PXBFMLJZNCDSMP-UHFFFAOYSA-N 0.000 claims description 6
NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 claims description 5
210000004369 blood Anatomy 0.000 claims description 5
239000008280 blood Substances 0.000 claims description 5
230000003647 oxidation Effects 0.000 claims description 5
238000007254 oxidation reaction Methods 0.000 claims description 5
239000008194 pharmaceutical composition Substances 0.000 claims description 5
206010038997 Retroviral infections Diseases 0.000 claims description 4
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 4
108020005202 Viral DNA Proteins 0.000 claims description 4
230000000368 destabilizing effect Effects 0.000 claims description 4
201000010099 disease Diseases 0.000 claims description 4
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
238000004519 manufacturing process Methods 0.000 claims description 4
230000008569 process Effects 0.000 claims description 4
LIWTYQKCNQKXHQ-UHFFFAOYSA-N 2-nitrosoisoquinolin-1-one Chemical compound C1=CC=C2C(=O)N(N=O)C=CC2=C1 LIWTYQKCNQKXHQ-UHFFFAOYSA-N 0.000 claims description 3
208000031886 HIV Infections Diseases 0.000 claims description 3
239000000706 filtrate Substances 0.000 claims description 3
239000002244 precipitate Substances 0.000 claims description 3
238000001556 precipitation Methods 0.000 claims description 3
238000001953 recrystallisation Methods 0.000 claims description 3
150000001408 amides Chemical class 0.000 claims description 2
238000001035 drying Methods 0.000 claims description 2
230000001590 oxidative effect Effects 0.000 claims description 2
229910000029 sodium carbonate Inorganic materials 0.000 claims description 2
238000001914 filtration Methods 0.000 claims 2
208000037357 HIV infectious disease Diseases 0.000 claims 1
208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims 1
208000036142 Viral infection Diseases 0.000 abstract description 5
230000009385 viral infection Effects 0.000 abstract description 5
210000004027 cell Anatomy 0.000 description 99
239000011701 zinc Substances 0.000 description 58
230000000694 effects Effects 0.000 description 57
229940079593 drug Drugs 0.000 description 43
239000003814 drug Substances 0.000 description 43
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 41
229910052725 zinc Inorganic materials 0.000 description 41
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 33
238000003556 assay Methods 0.000 description 29
230000005764 inhibitory process Effects 0.000 description 28
241000713311 Simian immunodeficiency virus Species 0.000 description 26
108020004414 DNA Proteins 0.000 description 24
102100034343 Integrase Human genes 0.000 description 23
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 21
229960000956 coumarin Drugs 0.000 description 21
238000002474 experimental method Methods 0.000 description 20
108010092799 RNA-directed DNA polymerase Proteins 0.000 description 17
239000003446 ligand Substances 0.000 description 17
239000003112 inhibitor Substances 0.000 description 14
230000015572 biosynthetic process Effects 0.000 description 13
230000002401 inhibitory effect Effects 0.000 description 13
238000011533 pre-incubation Methods 0.000 description 13
239000000243 solution Substances 0.000 description 13
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
238000012360 testing method Methods 0.000 description 12
239000000047 product Substances 0.000 description 11
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
WFFLPVBJUXVNNI-UHFFFAOYSA-N 2-nitrosobenzamide Chemical compound NC(=O)C1=CC=CC=C1N=O WFFLPVBJUXVNNI-UHFFFAOYSA-N 0.000 description 10
238000005481 NMR spectroscopy Methods 0.000 description 10
230000009471 action Effects 0.000 description 10
230000000840 anti-viral effect Effects 0.000 description 10
ZYGHJZDHTFUPRJ-UHFFFAOYSA-N coumarin Chemical compound C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 10
AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 10
230000003389 potentiating effect Effects 0.000 description 10
ZOJAINJCZSVZGW-UHFFFAOYSA-N 6-aminochromen-2-one Chemical class O1C(=O)C=CC2=CC(N)=CC=C21 ZOJAINJCZSVZGW-UHFFFAOYSA-N 0.000 description 9
102000004190 Enzymes Human genes 0.000 description 9
108090000790 Enzymes Proteins 0.000 description 9
108091005804 Peptidases Proteins 0.000 description 9
239000004365 Protease Substances 0.000 description 9
102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 9
239000003102 growth factor Substances 0.000 description 9
238000011534 incubation Methods 0.000 description 9
210000004698 lymphocyte Anatomy 0.000 description 9
238000003752 polymerase chain reaction Methods 0.000 description 9
239000002243 precursor Substances 0.000 description 9
108090000623 proteins and genes Proteins 0.000 description 9
238000004113 cell culture Methods 0.000 description 8
238000006243 chemical reaction Methods 0.000 description 8
108020004707 nucleic acids Proteins 0.000 description 8
102000039446 nucleic acids Human genes 0.000 description 8
150000007523 nucleic acids Chemical class 0.000 description 8
108090000765 processed proteins & peptides Proteins 0.000 description 8
102000004169 proteins and genes Human genes 0.000 description 8
230000010076 replication Effects 0.000 description 8
239000000126 substance Substances 0.000 description 8
101710205625 Capsid protein p24 Proteins 0.000 description 7
101710177166 Phosphoprotein Proteins 0.000 description 7
101710149279 Small delta antigen Proteins 0.000 description 7
102100031987 Transmembrane emp24 domain-containing protein 2 Human genes 0.000 description 7
238000002835 absorbance Methods 0.000 description 7
108091007433 antigens Proteins 0.000 description 7
102000036639 antigens Human genes 0.000 description 7
238000010790 dilution Methods 0.000 description 7
239000012895 dilution Substances 0.000 description 7
229940093499 ethyl acetate Drugs 0.000 description 7
235000019439 ethyl acetate Nutrition 0.000 description 7
230000012010 growth Effects 0.000 description 7
230000002779 inactivation Effects 0.000 description 7
230000001566 pro-viral effect Effects 0.000 description 7
239000000725 suspension Substances 0.000 description 7
210000004881 tumor cell Anatomy 0.000 description 7
108091003079 Bovine Serum Albumin Proteins 0.000 description 6
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
102000012338 Poly(ADP-ribose) Polymerases Human genes 0.000 description 6
108010061844 Poly(ADP-ribose) Polymerases Proteins 0.000 description 6
229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 description 6
108010071811 Simian immunodeficiency virus Gag protein p27 Proteins 0.000 description 6
238000004458 analytical method Methods 0.000 description 6
230000000259 anti-tumor effect Effects 0.000 description 6
239000000427 antigen Substances 0.000 description 6
230000001419 dependent effect Effects 0.000 description 6
230000006870 function Effects 0.000 description 6
208000032839 leukemia Diseases 0.000 description 6
230000009467 reduction Effects 0.000 description 6
239000002904 solvent Substances 0.000 description 6
238000003786 synthesis reaction Methods 0.000 description 6
OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 6
229960004528 vincristine Drugs 0.000 description 6
OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 6
210000002845 virion Anatomy 0.000 description 6
108010061833 Integrases Proteins 0.000 description 5
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 5
239000003443 antiviral agent Substances 0.000 description 5
239000012091 fetal bovine serum Substances 0.000 description 5
239000000463 material Substances 0.000 description 5
150000003839 salts Chemical class 0.000 description 5
238000001228 spectrum Methods 0.000 description 5
239000006228 supernatant Substances 0.000 description 5
230000035899 viability Effects 0.000 description 5
230000029812 viral genome replication Effects 0.000 description 5
MTQVCSMMHKUIMU-UHFFFAOYSA-N 4-nitrosobenzamide Chemical compound NC(=O)C1=CC=C(N=O)C=C1 MTQVCSMMHKUIMU-UHFFFAOYSA-N 0.000 description 4
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
210000001744 T-lymphocyte Anatomy 0.000 description 4
230000036436 anti-hiv Effects 0.000 description 4
125000003118 aryl group Chemical group 0.000 description 4
125000005337 azoxy group Chemical group [N+]([O-])(=N*)* 0.000 description 4
210000001185 bone marrow Anatomy 0.000 description 4
QAIPRVGONGVQAS-DUXPYHPUSA-N caffeic acid Natural products OC(=O)\C=C\C1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-DUXPYHPUSA-N 0.000 description 4
230000003833 cell viability Effects 0.000 description 4
230000001413 cellular effect Effects 0.000 description 4
230000000445 cytocidal effect Effects 0.000 description 4
238000009472 formulation Methods 0.000 description 4
239000012535 impurity Substances 0.000 description 4
230000010354 integration Effects 0.000 description 4
VDBNYAPERZTOOF-UHFFFAOYSA-N isoquinolin-1(2H)-one Chemical compound C1=CC=C2C(=O)NC=CC2=C1 VDBNYAPERZTOOF-UHFFFAOYSA-N 0.000 description 4
239000002609 medium Substances 0.000 description 4
238000004806 packaging method and process Methods 0.000 description 4
210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 4
229920001184 polypeptide Polymers 0.000 description 4
102000004196 processed proteins & peptides Human genes 0.000 description 4
230000035755 proliferation Effects 0.000 description 4
230000002829 reductive effect Effects 0.000 description 4
238000010839 reverse transcription Methods 0.000 description 4
239000000523 sample Substances 0.000 description 4
239000007787 solid Substances 0.000 description 4
210000000130 stem cell Anatomy 0.000 description 4
210000001519 tissue Anatomy 0.000 description 4
ACEAELOMUCBPJP-UHFFFAOYSA-N (E)-3,4,5-trihydroxycinnamic acid Natural products OC(=O)C=CC1=CC(O)=C(O)C(O)=C1 ACEAELOMUCBPJP-UHFFFAOYSA-N 0.000 description 3
AMOYMEBHYUTMKJ-UHFFFAOYSA-N 2-(2-phenylethoxy)ethylbenzene Chemical compound C=1C=CC=CC=1CCOCCC1=CC=CC=C1 AMOYMEBHYUTMKJ-UHFFFAOYSA-N 0.000 description 3
101710132601 Capsid protein Proteins 0.000 description 3
238000002965 ELISA Methods 0.000 description 3
241000726306 Irus Species 0.000 description 3
241000282560 Macaca mulatta Species 0.000 description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
241001529936 Murinae Species 0.000 description 3
102000007999 Nuclear Proteins Human genes 0.000 description 3
108010089610 Nuclear Proteins Proteins 0.000 description 3
102400001093 PAK-2p27 Human genes 0.000 description 3
108010047620 Phytohemagglutinins Proteins 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 3
OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 3
102000004357 Transferases Human genes 0.000 description 3
108090000992 Transferases Proteins 0.000 description 3
239000002253 acid Substances 0.000 description 3
150000007513 acids Chemical class 0.000 description 3
230000003321 amplification Effects 0.000 description 3
229960005070 ascorbic acid Drugs 0.000 description 3
239000011668 ascorbic acid Substances 0.000 description 3
238000000376 autoradiography Methods 0.000 description 3
235000004883 caffeic acid Nutrition 0.000 description 3
229940074360 caffeic acid Drugs 0.000 description 3
230000010261 cell growth Effects 0.000 description 3
239000007795 chemical reaction product Substances 0.000 description 3
239000003795 chemical substances by application Substances 0.000 description 3
230000000973 chemotherapeutic effect Effects 0.000 description 3
QAIPRVGONGVQAS-UHFFFAOYSA-N cis-caffeic acid Natural products OC(=O)C=CC1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-UHFFFAOYSA-N 0.000 description 3
238000003776 cleavage reaction Methods 0.000 description 3
239000000539 dimer Substances 0.000 description 3
239000000499 gel Substances 0.000 description 3
238000003018 immunoassay Methods 0.000 description 3
150000002500 ions Chemical class 0.000 description 3
210000000265 leukocyte Anatomy 0.000 description 3
239000007788 liquid Substances 0.000 description 3
238000001819 mass spectrum Methods 0.000 description 3
230000007246 mechanism Effects 0.000 description 3
239000000155 melt Substances 0.000 description 3
238000002844 melting Methods 0.000 description 3
230000008018 melting Effects 0.000 description 3
230000002503 metabolic effect Effects 0.000 description 3
231100000252 nontoxic Toxicity 0.000 description 3
238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 3
238000003199 nucleic acid amplification method Methods 0.000 description 3
239000011886 peripheral blood Substances 0.000 description 3
230000002093 peripheral effect Effects 0.000 description 3
230000001885 phytohemagglutinin Effects 0.000 description 3
239000013641 positive control Substances 0.000 description 3
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
239000011541 reaction mixture Substances 0.000 description 3
230000002441 reversible effect Effects 0.000 description 3
230000007017 scission Effects 0.000 description 3
239000011780 sodium chloride Substances 0.000 description 3
238000003756 stirring Methods 0.000 description 3
239000000758 substrate Substances 0.000 description 3
238000004809 thin layer chromatography Methods 0.000 description 3
231100000331 toxic Toxicity 0.000 description 3
230000002588 toxic effect Effects 0.000 description 3
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
GSCPDZHWVNUUFI-UHFFFAOYSA-N 3-aminobenzamide Chemical compound NC(=O)C1=CC=CC(N)=C1 GSCPDZHWVNUUFI-UHFFFAOYSA-N 0.000 description 2
LULAYUGMBFYYEX-UHFFFAOYSA-N 3-chlorobenzoic acid Chemical compound OC(=O)C1=CC=CC(Cl)=C1 LULAYUGMBFYYEX-UHFFFAOYSA-N 0.000 description 2
WWRAFPGUBABZSD-UHFFFAOYSA-N 6-amino-5-iodochromen-2-one Chemical compound O1C(=O)C=CC2=C(I)C(N)=CC=C21 WWRAFPGUBABZSD-UHFFFAOYSA-N 0.000 description 2
208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 2
208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 2
229920001817 Agar Polymers 0.000 description 2
KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 2
206010006187 Breast cancer Diseases 0.000 description 2
208000026310 Breast neoplasm Diseases 0.000 description 2
CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 2
HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 2
102000003915 DNA Topoisomerases Human genes 0.000 description 2
108090000323 DNA Topoisomerases Proteins 0.000 description 2
230000004568 DNA-binding Effects 0.000 description 2
IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
108700020129 Human immunodeficiency virus 1 p31 integrase Proteins 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
231100000002 MTT assay Toxicity 0.000 description 2
238000000134 MTT assay Methods 0.000 description 2
206010064912 Malignant transformation Diseases 0.000 description 2
BAWFJGJZGIEFAR-NNYOXOHSSA-O NAD(+) Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-O 0.000 description 2
108091034117 Oligonucleotide Proteins 0.000 description 2
102000043276 Oncogene Human genes 0.000 description 2
108700020796 Oncogene Proteins 0.000 description 2
238000002944 PCR assay Methods 0.000 description 2
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 2
REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 2
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
238000010521 absorption reaction Methods 0.000 description 2
OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
239000008272 agar Substances 0.000 description 2
239000011543 agarose gel Substances 0.000 description 2
HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 2
230000000798 anti-retroviral effect Effects 0.000 description 2
235000010323 ascorbic acid Nutrition 0.000 description 2
230000003305 autocrine Effects 0.000 description 2
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 2
239000000872 buffer Substances 0.000 description 2
239000006227 byproduct Substances 0.000 description 2
230000000711 cancerogenic effect Effects 0.000 description 2
231100000357 carcinogen Toxicity 0.000 description 2
239000003183 carcinogenic agent Substances 0.000 description 2
210000000170 cell membrane Anatomy 0.000 description 2
230000019522 cellular metabolic process Effects 0.000 description 2
OTAFHZMPRISVEM-UHFFFAOYSA-N chromone Chemical compound C1=CC=C2C(=O)C=COC2=C1 OTAFHZMPRISVEM-UHFFFAOYSA-N 0.000 description 2
235000001671 coumarin Nutrition 0.000 description 2
239000000824 cytostatic agent Substances 0.000 description 2
230000001085 cytostatic effect Effects 0.000 description 2
229940127089 cytotoxic agent Drugs 0.000 description 2
230000000994 depressogenic effect Effects 0.000 description 2
230000001687 destabilization Effects 0.000 description 2
238000011161 development Methods 0.000 description 2
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 2
NLFBCYMMUAKCPC-KQQUZDAGSA-N ethyl (e)-3-[3-amino-2-cyano-1-[(e)-3-ethoxy-3-oxoprop-1-enyl]sulfanyl-3-oxoprop-1-enyl]sulfanylprop-2-enoate Chemical compound CCOC(=O)\C=C\SC(=C(C#N)C(N)=O)S\C=C\C(=O)OCC NLFBCYMMUAKCPC-KQQUZDAGSA-N 0.000 description 2
238000001704 evaporation Methods 0.000 description 2
230000008020 evaporation Effects 0.000 description 2
238000000684 flow cytometry Methods 0.000 description 2
230000009422 growth inhibiting effect Effects 0.000 description 2
150000008282 halocarbons Chemical class 0.000 description 2
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
230000036212 malign transformation Effects 0.000 description 2
238000012986 modification Methods 0.000 description 2
230000004048 modification Effects 0.000 description 2
210000004493 neutrocyte Anatomy 0.000 description 2
230000003000 nontoxic effect Effects 0.000 description 2
239000002245 particle Substances 0.000 description 2
210000005259 peripheral blood Anatomy 0.000 description 2
239000000546 pharmaceutical excipient Substances 0.000 description 2
239000002953 phosphate buffered saline Substances 0.000 description 2
150000003904 phospholipids Chemical class 0.000 description 2
238000006116 polymerization reaction Methods 0.000 description 2
238000002976 reverse transcriptase assay Methods 0.000 description 2
238000002741 site-directed mutagenesis Methods 0.000 description 2
239000011734 sodium Substances 0.000 description 2
229910052708 sodium Inorganic materials 0.000 description 2
239000012265 solid product Substances 0.000 description 2
230000003595 spectral effect Effects 0.000 description 2
239000000829 suppository Substances 0.000 description 2
125000003831 tetrazolyl group Chemical group 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
238000011200 topical administration Methods 0.000 description 2
230000001988 toxicity Effects 0.000 description 2
231100000419 toxicity Toxicity 0.000 description 2
230000007501 viral attachment Effects 0.000 description 2
DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
ICLYJLBTOGPLMC-KVVVOXFISA-N (z)-octadec-9-enoate;tris(2-hydroxyethyl)azanium Chemical compound OCCN(CCO)CCO.CCCCCCCC\C=C/CCCCCCCC(O)=O ICLYJLBTOGPLMC-KVVVOXFISA-N 0.000 description 1
HTSGKJQDMSTCGS-UHFFFAOYSA-N 1,4-bis(4-chlorophenyl)-2-(4-methylphenyl)sulfonylbutane-1,4-dione Chemical compound C1=CC(C)=CC=C1S(=O)(=O)C(C(=O)C=1C=CC(Cl)=CC=1)CC(=O)C1=CC=C(Cl)C=C1 HTSGKJQDMSTCGS-UHFFFAOYSA-N 0.000 description 1
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
KDZPPKQYVFWGGV-UHFFFAOYSA-N 2-aminoisoquinolin-1-one Chemical class C1=CC=C2C(=O)N(N)C=CC2=C1 KDZPPKQYVFWGGV-UHFFFAOYSA-N 0.000 description 1
ULQQGOGMQRGFFR-UHFFFAOYSA-N 2-chlorobenzenecarboperoxoic acid Chemical compound OOC(=O)C1=CC=CC=C1Cl ULQQGOGMQRGFFR-UHFFFAOYSA-N 0.000 description 1
CGACGSHTSCXSSO-UHFFFAOYSA-N 2h-1,3-benzoxazine Chemical compound C1=CC=C2C=NCOC2=C1 CGACGSHTSCXSSO-UHFFFAOYSA-N 0.000 description 1
QWZHDKGQKYEBKK-UHFFFAOYSA-N 3-aminochromen-2-one Chemical compound C1=CC=C2OC(=O)C(N)=CC2=C1 QWZHDKGQKYEBKK-UHFFFAOYSA-N 0.000 description 1
QIKYZXDTTPVVAC-UHFFFAOYSA-N 4-Aminobenzamide Chemical compound NC(=O)C1=CC=C(N)C=C1 QIKYZXDTTPVVAC-UHFFFAOYSA-N 0.000 description 1
VMLHPUMZIKVELK-UHFFFAOYSA-N 4-amino-2h-isoquinolin-1-one Chemical compound C1=CC=C2C(N)=CNC(=O)C2=C1 VMLHPUMZIKVELK-UHFFFAOYSA-N 0.000 description 1
AHZAKFLOHIRCDU-UHFFFAOYSA-N 4-aminochromen-2-one Chemical compound C1=CC=CC2=C1OC(=O)C=C2N AHZAKFLOHIRCDU-UHFFFAOYSA-N 0.000 description 1
MUTWEAVAMRJILI-UHFFFAOYSA-N 5-aminochromen-2-one Chemical compound O1C(=O)C=CC2=C1C=CC=C2N MUTWEAVAMRJILI-UHFFFAOYSA-N 0.000 description 1
VFTOHJFKIJLYKN-UHFFFAOYSA-N 7-nitro-9h-fluoren-2-ol Chemical group [O-][N+](=O)C1=CC=C2C3=CC=C(O)C=C3CC2=C1 VFTOHJFKIJLYKN-UHFFFAOYSA-N 0.000 description 1
230000005730 ADP ribosylation Effects 0.000 description 1
SRNWOUGRCWSEMX-KEOHHSTQSA-N ADP-beta-D-ribose Chemical group C([C@H]1O[C@H]([C@@H]([C@@H]1O)O)N1C=2N=CN=C(C=2N=C1)N)OP(O)(=O)OP(O)(=O)OC[C@H]1O[C@@H](O)[C@H](O)[C@@H]1O SRNWOUGRCWSEMX-KEOHHSTQSA-N 0.000 description 1
208000030507 AIDS Diseases 0.000 description 1
108010085238 Actins Proteins 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
101001053401 Arabidopsis thaliana Acid beta-fructofuranosidase 3, vacuolar Proteins 0.000 description 1
101100515517 Arabidopsis thaliana XI-I gene Proteins 0.000 description 1
208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
208000003174 Brain Neoplasms Diseases 0.000 description 1
150000004006 C-nitroso compounds Chemical class 0.000 description 1
239000002126 C01EB10 - Adenosine Substances 0.000 description 1
101150041968 CDC13 gene Proteins 0.000 description 1
108010077544 Chromatin Proteins 0.000 description 1
208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
241000699800 Cricetinae Species 0.000 description 1
ZGRQPKYPJYNOKX-XUXIUFHCSA-N Cys-Cys-His-His Chemical compound C([C@H](NC(=O)[C@H](CS)NC(=O)[C@H](CS)N)C(=O)N[C@@H](CC=1NC=NC=1)C(O)=O)C1=CN=CN1 ZGRQPKYPJYNOKX-XUXIUFHCSA-N 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
238000007400 DNA extraction Methods 0.000 description 1
238000012270 DNA recombination Methods 0.000 description 1
230000004543 DNA replication Effects 0.000 description 1
230000007018 DNA scission Effects 0.000 description 1
230000006820 DNA synthesis Effects 0.000 description 1
102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
238000008157 ELISA kit Methods 0.000 description 1
241000588724 Escherichia coli Species 0.000 description 1
241000206602 Eukaryota Species 0.000 description 1
101710177291 Gag polyprotein Proteins 0.000 description 1
241001427367 Gardena Species 0.000 description 1
239000007995 HEPES buffer Substances 0.000 description 1
238000010268 HPLC based assay Methods 0.000 description 1
101000852483 Homo sapiens Interleukin-1 receptor-associated kinase 1 Proteins 0.000 description 1
108700043000 Human immunodeficiency virus 1 NCP7 Proteins 0.000 description 1
108010016183 Human immunodeficiency virus 1 p16 protease Proteins 0.000 description 1
101900297506 Human immunodeficiency virus type 1 group M subtype B Reverse transcriptase/ribonuclease H Proteins 0.000 description 1
208000001953 Hypotension Diseases 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
108010070716 Intercellular Signaling Peptides and Proteins Proteins 0.000 description 1
102000005755 Intercellular Signaling Peptides and Proteins Human genes 0.000 description 1
102100036342 Interleukin-1 receptor-associated kinase 1 Human genes 0.000 description 1
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
229930182816 L-glutamine Natural products 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
241000282553 Macaca Species 0.000 description 1
101710125418 Major capsid protein Proteins 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
108010036176 Melitten Proteins 0.000 description 1
241000699666 Mus <mouse, genus> Species 0.000 description 1
101100407078 Mus musculus Parp1 gene Proteins 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
239000000020 Nitrocellulose Substances 0.000 description 1
206010067482 No adverse event Diseases 0.000 description 1
238000010222 PCR analysis Methods 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
239000012980 RPMI-1640 medium Substances 0.000 description 1
241000220010 Rhode Species 0.000 description 1
HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
WINXNKPZLFISPD-UHFFFAOYSA-M Saccharin sodium Chemical compound [Na+].C1=CC=C2C(=O)[N-]S(=O)(=O)C2=C1 WINXNKPZLFISPD-UHFFFAOYSA-M 0.000 description 1
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
240000006394 Sorghum bicolor Species 0.000 description 1
235000011684 Sorghum saccharatum Nutrition 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
235000009430 Thespesia populnea Nutrition 0.000 description 1
HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 1
229920004890 Triton X-100 Polymers 0.000 description 1
239000013504 Triton X-100 Substances 0.000 description 1
102000007537 Type II DNA Topoisomerases Human genes 0.000 description 1
108010046308 Type II DNA Topoisomerases Proteins 0.000 description 1
108010015780 Viral Core Proteins Proteins 0.000 description 1
108010067390 Viral Proteins Proteins 0.000 description 1
108020000999 Viral RNA Proteins 0.000 description 1
101710185494 Zinc finger protein Proteins 0.000 description 1
102100023597 Zinc finger protein 816 Human genes 0.000 description 1
ICNHOLCERMYLRZ-KEOHHSTQSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2r,3s,4r,5r)-3,4,5-trihydroxyoxolan-2-yl]methyl hydrogen phosphate Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H]1O)OP(O)(O)=O)N1C=2N=CN=C(C=2N=C1)N)OP(O)(=O)OP(O)(=O)OC[C@H]1O[C@@H](O)[C@H](O)[C@@H]1O ICNHOLCERMYLRZ-KEOHHSTQSA-N 0.000 description 1
GLWHPRRGGYLLRV-XLPZGREQSA-N [[(2s,3s,5r)-3-azido-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](N=[N+]=[N-])C1 GLWHPRRGGYLLRV-XLPZGREQSA-N 0.000 description 1
DJDQJUULNCHIGO-JGVFFNPUSA-N [[(2s,5r)-5-(3-azido-5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound O=C1N(N=[N+]=[N-])C(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)CC1 DJDQJUULNCHIGO-JGVFFNPUSA-N 0.000 description 1
238000000862 absorption spectrum Methods 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
229960005305 adenosine Drugs 0.000 description 1
125000001722 adenosinediphosphoribosyl group Chemical group 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
230000002908 adrenolytic effect Effects 0.000 description 1
230000002411 adverse Effects 0.000 description 1
125000000217 alkyl group Chemical group 0.000 description 1
150000001413 amino acids Chemical group 0.000 description 1
238000004873 anchoring Methods 0.000 description 1
230000008485 antagonism Effects 0.000 description 1
230000001093 anti-cancer Effects 0.000 description 1
230000000719 anti-leukaemic effect Effects 0.000 description 1
230000001754 anti-pyretic effect Effects 0.000 description 1
230000000417 anti-transforming effect Effects 0.000 description 1
230000002622 anti-tumorigenesis Effects 0.000 description 1
239000002221 antipyretic Substances 0.000 description 1
230000006907 apoptotic process Effects 0.000 description 1
238000013459 approach Methods 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
210000003719 b-lymphocyte Anatomy 0.000 description 1
239000002585 base Substances 0.000 description 1
229940054066 benzamide antipsychotics Drugs 0.000 description 1
150000003936 benzamides Chemical class 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
230000031018 biological processes and functions Effects 0.000 description 1
239000012888 bovine serum Substances 0.000 description 1
244000309464 bull Species 0.000 description 1
244000309466 calf Species 0.000 description 1
230000003327 cancerostatic effect Effects 0.000 description 1
239000002775 capsule Substances 0.000 description 1
239000000969 carrier Substances 0.000 description 1
239000003054 catalyst Substances 0.000 description 1
230000034303 cell budding Effects 0.000 description 1
230000022131 cell cycle Effects 0.000 description 1
230000004663 cell proliferation Effects 0.000 description 1
230000015861 cell surface binding Effects 0.000 description 1
239000006285 cell suspension Substances 0.000 description 1
238000013043 cell viability test Methods 0.000 description 1
230000007541 cellular toxicity Effects 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
230000008859 change Effects 0.000 description 1
239000003638 chemical reducing agent Substances 0.000 description 1
230000005929 chemotherapeutic response Effects 0.000 description 1
238000002512 chemotherapy Methods 0.000 description 1
210000003483 chromatin Anatomy 0.000 description 1
230000005757 colony formation Effects 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
239000002131 composite material Substances 0.000 description 1
239000013078 crystal Substances 0.000 description 1
239000012531 culture fluid Substances 0.000 description 1
239000012228 culture supernatant Substances 0.000 description 1
238000012258 culturing Methods 0.000 description 1
230000000120 cytopathologic effect Effects 0.000 description 1
231100000433 cytotoxic Toxicity 0.000 description 1
230000001472 cytotoxic effect Effects 0.000 description 1
230000003013 cytotoxicity Effects 0.000 description 1
231100000135 cytotoxicity Toxicity 0.000 description 1
230000006378 damage Effects 0.000 description 1
238000000354 decomposition reaction Methods 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000002950 deficient Effects 0.000 description 1
239000008367 deionised water Substances 0.000 description 1
229910021641 deionized water Inorganic materials 0.000 description 1
238000012217 deletion Methods 0.000 description 1
230000037430 deletion Effects 0.000 description 1
229960000633 dextran sulfate Drugs 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
230000003292 diminished effect Effects 0.000 description 1
238000010494 dissociation reaction Methods 0.000 description 1
230000005593 dissociations Effects 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
241001493065 dsRNA viruses Species 0.000 description 1
239000012039 electrophile Substances 0.000 description 1
238000001962 electrophoresis Methods 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
238000001952 enzyme assay Methods 0.000 description 1
238000011067 equilibration Methods 0.000 description 1
210000003527 eukaryotic cell Anatomy 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
239000013604 expression vector Substances 0.000 description 1
239000000284 extract Substances 0.000 description 1
238000000605 extraction Methods 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
239000012894 fetal calf serum Substances 0.000 description 1
230000001605 fetal effect Effects 0.000 description 1
210000002950 fibroblast Anatomy 0.000 description 1
239000012530 fluid Substances 0.000 description 1
239000012458 free base Substances 0.000 description 1
230000004927 fusion Effects 0.000 description 1
108700004026 gag Genes Proteins 0.000 description 1
101150098622 gag gene Proteins 0.000 description 1
238000007429 general method Methods 0.000 description 1
208000005017 glioblastoma Diseases 0.000 description 1
239000008103 glucose Substances 0.000 description 1
230000005484 gravity Effects 0.000 description 1
230000009036 growth inhibition Effects 0.000 description 1
125000000623 heterocyclic group Chemical group 0.000 description 1
229920001519 homopolymer Polymers 0.000 description 1
238000009396 hybridization Methods 0.000 description 1
230000000147 hypnotic effect Effects 0.000 description 1
208000021822 hypotensive Diseases 0.000 description 1
230000001077 hypotensive effect Effects 0.000 description 1
230000002631 hypothermal effect Effects 0.000 description 1
238000002513 implantation Methods 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
230000006698 induction Effects 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
238000001802 infusion Methods 0.000 description 1
239000007972 injectable composition Substances 0.000 description 1
229940102223 injectable solution Drugs 0.000 description 1
229940102213 injectable suspension Drugs 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
238000010255 intramuscular injection Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
125000002346 iodo group Chemical group I* 0.000 description 1
MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
230000002147 killing effect Effects 0.000 description 1
239000008101 lactose Substances 0.000 description 1
230000003902 lesion Effects 0.000 description 1
230000031700 light absorption Effects 0.000 description 1
239000002502 liposome Substances 0.000 description 1
239000008297 liquid dosage form Substances 0.000 description 1
239000006193 liquid solution Substances 0.000 description 1
239000006194 liquid suspension Substances 0.000 description 1
108010063243 low molecular weight-B cell growth factor Proteins 0.000 description 1
231100000053 low toxicity Toxicity 0.000 description 1
ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
239000001095 magnesium carbonate Substances 0.000 description 1
229910000021 magnesium carbonate Inorganic materials 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
230000036210 malignancy Effects 0.000 description 1
210000004962 mammalian cell Anatomy 0.000 description 1
210000001161 mammalian embryo Anatomy 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
239000003550 marker Substances 0.000 description 1
230000010534 mechanism of action Effects 0.000 description 1
VDXZNPDIRNWWCW-JFTDCZMZSA-N melittin Chemical compound NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(N)=O)CC1=CNC2=CC=CC=C12 VDXZNPDIRNWWCW-JFTDCZMZSA-N 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
238000000386 microscopy Methods 0.000 description 1
230000002297 mitogenic effect Effects 0.000 description 1
238000002156 mixing Methods 0.000 description 1
239000003147 molecular marker Substances 0.000 description 1
239000003068 molecular probe Substances 0.000 description 1
210000005087 mononuclear cell Anatomy 0.000 description 1
238000002703 mutagenesis Methods 0.000 description 1
208000025113 myeloid leukemia Diseases 0.000 description 1
APVPOHHVBBYQAV-UHFFFAOYSA-N n-(4-aminophenyl)sulfonyloctadecanamide Chemical compound CCCCCCCCCCCCCCCCCC(=O)NS(=O)(=O)C1=CC=C(N)C=C1 APVPOHHVBBYQAV-UHFFFAOYSA-N 0.000 description 1
229950006238 nadide Drugs 0.000 description 1
239000013642 negative control Substances 0.000 description 1
230000009826 neoplastic cell growth Effects 0.000 description 1
210000000440 neutrophil Anatomy 0.000 description 1
235000005152 nicotinamide Nutrition 0.000 description 1
150000005480 nicotinamides Chemical class 0.000 description 1
238000006396 nitration reaction Methods 0.000 description 1
150000002828 nitro derivatives Chemical class 0.000 description 1
229920001220 nitrocellulos Polymers 0.000 description 1
210000004882 non-tumor cell Anatomy 0.000 description 1
230000009871 nonspecific binding Effects 0.000 description 1
210000004940 nucleus Anatomy 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
108010062490 p27 antigen Proteins 0.000 description 1
239000006179 pH buffering agent Substances 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
210000002568 pbsc Anatomy 0.000 description 1
239000008188 pellet Substances 0.000 description 1
230000008823 permeabilization Effects 0.000 description 1
239000012466 permeate Substances 0.000 description 1
150000004965 peroxy acids Chemical class 0.000 description 1
229940124531 pharmaceutical excipient Drugs 0.000 description 1
239000003186 pharmaceutical solution Substances 0.000 description 1
230000001766 physiological effect Effects 0.000 description 1
239000006187 pill Substances 0.000 description 1
239000013612 plasmid Substances 0.000 description 1
238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
229920001515 polyalkylene glycol Polymers 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
231100000683 possible toxicity Toxicity 0.000 description 1
239000011591 potassium Substances 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
239000000843 powder Substances 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
230000002265 prevention Effects 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
230000000644 propagated effect Effects 0.000 description 1
238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
229960001285 quercetin Drugs 0.000 description 1
235000005875 quercetin Nutrition 0.000 description 1
238000003127 radioimmunoassay Methods 0.000 description 1
238000011160 research Methods 0.000 description 1
230000004044 response Effects 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
238000002390 rotary evaporation Methods 0.000 description 1
239000000932 sedative agent Substances 0.000 description 1
230000001624 sedative effect Effects 0.000 description 1
239000008299 semisolid dosage form Substances 0.000 description 1
238000013207 serial dilution Methods 0.000 description 1
239000000741 silica gel Substances 0.000 description 1
229910002027 silica gel Inorganic materials 0.000 description 1
231100000188 sister chromatid exchange Toxicity 0.000 description 1
FLNVBBPBGKOJHN-KKAOYSRWSA-N sivmac Chemical compound O=C([C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CS)NC(=O)[C@@H](N)CCCNC(N)=N)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)[C@@H](C)CC)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(O)=O FLNVBBPBGKOJHN-KKAOYSRWSA-N 0.000 description 1
239000001632 sodium acetate Substances 0.000 description 1
235000017281 sodium acetate Nutrition 0.000 description 1
235000017557 sodium bicarbonate Nutrition 0.000 description 1
229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
235000017550 sodium carbonate Nutrition 0.000 description 1
159000000000 sodium salts Chemical class 0.000 description 1
229910052938 sodium sulfate Inorganic materials 0.000 description 1
235000011152 sodium sulphate Nutrition 0.000 description 1
XMVONEAAOPAGAO-UHFFFAOYSA-N sodium tungstate Chemical compound [Na+].[Na+].[O-][W]([O-])(=O)=O XMVONEAAOPAGAO-UHFFFAOYSA-N 0.000 description 1
239000008279 sol Substances 0.000 description 1
239000007909 solid dosage form Substances 0.000 description 1
239000008247 solid mixture Substances 0.000 description 1
230000003381 solubilizing effect Effects 0.000 description 1
238000004611 spectroscopical analysis Methods 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000000021 stimulant Substances 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
239000011550 stock solution Substances 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
238000013268 sustained release Methods 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
239000003826 tablet Substances 0.000 description 1
239000000454 talc Substances 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
229940104230 thymidine Drugs 0.000 description 1
210000001541 thymus gland Anatomy 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
231100000816 toxic dose Toxicity 0.000 description 1
238000002723 toxicity assay Methods 0.000 description 1
230000007704 transition Effects 0.000 description 1
229940117013 triethanolamine oleate Drugs 0.000 description 1
230000001173 tumoral effect Effects 0.000 description 1
231100000588 tumorigenic Toxicity 0.000 description 1
230000000381 tumorigenic effect Effects 0.000 description 1
238000001429 visible spectrum Methods 0.000 description 1
238000010792 warming Methods 0.000 description 1
238000009736 wetting Methods 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
- A61K31/37—Coumarins, e.g. psoralen
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Chemical & Material Sciences (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Virology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Molecular Biology (AREA)
Tropical Medicine & Parasitology (AREA)
AIDS & HIV (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Pyrane Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Other In-Based Heterocyclic Compounds (AREA)

CA002148455A 1992-11-02 1993-10-04 Composes nitrosoaromatiques lies a l'adenosine-diphosphoribose-polymerase, utiles comme agents anti-retroviraux et anti-tumeurs Abandoned CA2148455A1 (fr)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US07/965,541 US5516941A (en)	1991-10-22	1992-11-02	Specific inactivators of "retroviral" (asymmetric) zinc fingers
US07/965,541		1992-11-02
US8756693A	1993-07-02	1993-07-02
US08/087,566		1993-07-02

Publications (1)

Publication Number	Publication Date
CA2148455A1 true CA2148455A1 (fr)	1994-05-11

Family

ID=26777121

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002148455A Abandoned CA2148455A1 (fr)	1992-11-02	1993-10-04	Composes nitrosoaromatiques lies a l'adenosine-diphosphoribose-polymerase, utiles comme agents anti-retroviraux et anti-tumeurs

Country Status (6)

Country	Link
EP (1)	EP0666742A1 (fr)
JP (1)	JPH10504517A (fr)
AU (1)	AU5298693A (fr)
CA (1)	CA2148455A1 (fr)
IL (1)	IL107249A0 (fr)
WO (1)	WO1994009776A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5464871A (en)	1993-05-12	1995-11-07	Octamer, Inc.	Aromatic nitro and nitroso compounds and their metabolites useful as anti-viral and anti-tumor agents
US5877185A (en) *	1991-10-22	1999-03-02	Octamer, Inc.	Synergistic compositions useful as anti-tumor agents
US11433074B2 (en)	2017-06-22	2022-09-06	Triact Therapeutics, Inc.	Methods of treating glioblastoma
EP3687501A4 (fr)	2017-09-29	2021-06-23	Triact Therapeutics, Inc.	Formulations d'iniparib et leurs utilisations

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1991004663A1 (fr) *	1989-09-26	1991-04-18	The Regents Of The University Of California	6-amino-1,2-benzopyrones utiles dans le traitement de maladies virales
US5484951A (en) *	1990-10-19	1996-01-16	Octamer, Incorporated	5-iodo-6-amino-6-nitroso-1,2-benzopyrones useful as cytostatic and antiviral agents
JP3070767B2 (ja) *	1991-10-22	2000-07-31	オクタマー，インコーポレイティド	抗腫瘍及び抗―レトロウィルス剤として有用なアデノシンジホスホリボースポリメラーゼ結合性ニトロソ芳香族化合物

1993
- 1993-10-04 CA CA002148455A patent/CA2148455A1/fr not_active Abandoned
- 1993-10-04 EP EP93923226A patent/EP0666742A1/fr not_active Withdrawn
- 1993-10-04 AU AU52986/93A patent/AU5298693A/en not_active Abandoned
- 1993-10-04 WO PCT/US1993/009457 patent/WO1994009776A1/fr not_active Ceased
- 1993-10-04 JP JP6511074A patent/JPH10504517A/ja not_active Ceased
- 1993-10-11 IL IL107249A patent/IL107249A0/xx unknown

Also Published As

Publication number	Publication date
IL107249A0 (en)	1994-01-25
EP0666742A1 (fr)	1995-08-16
JPH10504517A (ja)	1998-05-06
WO1994009776A1 (fr)	1994-05-11
AU5298693A (en)	1994-05-24

Legal Events

Date	Code	Title	Description
1998-10-05	FZDE	Discontinued

Publication	Publication Date	Title
US5753674A (en)	1998-05-19	Adenosine diphosphoribose polymerase binding nitroso aromatic compounds useful as retroviral inactivating agents, anti-retroviral agents, anti-retroviral agents and anti-tumor agents
US5516941A (en)	1996-05-14	Specific inactivators of "retroviral" (asymmetric) zinc fingers
US5482975A (en)	1996-01-09	Adenosine diphosphoribose polymerase binding nitroso aromatic compounds useful as retroviral inactivating agents, anti-retroviral agents and anti-tumor agents
US5473074A (en)	1995-12-05	Adenosine diphosphoribose polymerase binding nitroso aromatic compounds useful as retroviral inactivating agents, anti-retroviral agents and anti-tumor agents-54
KR0180019B1 (ko)	1999-03-20	개량된 화학적 화합물
EP0698019B1 (fr)	1998-08-05	Nouveaux composes aromatiques nitro et leurs metabolites, aptes a etre utilises comme agents antiviraux et antitumoraux
US5877185A (en)	1999-03-02	Synergistic compositions useful as anti-tumor agents
US5262564A (en)	1993-11-16	Sulfinic acid adducts of organo nitroso compounds useful as retroviral inactivating agents anti-retroviral agents and anti-tumor agents
HO et al.	1992	Glutathione and N-acetylcysteine suppression of human immunodeficiency virus replication in human monocyte/macrophages in vitro
WO1996022791A9 (fr)	1996-10-03	Nouvelles compositions synergiques antitumorales et antiretrovirales
JP4121151B2 (ja)	2008-07-23	抗新生物薬および抗レトロウイルス薬として有用なアクリドンから誘導された化合物
EP0494231A1 (fr)	1992-07-15	6-amino-1,2-benzopyrones utiles dans le traitement de maladies virales
WO1994004145A1 (fr)	1994-03-03	Traitement d'infections virales chez l'homme
EP0741569A1 (fr)	1996-11-13	Alcaloides du type naphthylisoquinoleine, preparations pharmaceutiques les contenant et leur emploi en vue du traitement de la malaria
AU676992B2 (en)	1997-04-10	Adenosine diphosphoribose polymerase binding nitroso aromatic compounds useful as anti-tumor and anti-retroviral agents
CA2148455A1 (fr)	1994-05-11	Composes nitrosoaromatiques lies a l'adenosine-diphosphoribose-polymerase, utiles comme agents anti-retroviraux et anti-tumeurs
US20060094755A1 (en)	2006-05-04	Novel quinoline-based metal chelators as antiviral agents
CA2189705C (fr)	2005-08-09	Utilisation de flupirtine pour la prevention et le traitement des maladies associees a la deficience du systeme cellulaire hematopoietique
Pantazis	1996	Camptothecin: a promising antiretroviral drug
WO1994004160A1 (fr)	1994-03-03	Traitement d'infections virales chez l'homme
US4971977A (en)	1990-11-20	Anti-viral pharmaceutical compositions
EP0416011A1 (fr)	1991-03-13	Composition chimiotherapeutique pour le traitement du sida
WO1994004139A1 (fr)	1994-03-03	Traitement d'infections virales chez l'homme
JP2003503455A (ja)	2003-01-28	抗ウイルス治療
US20060100282A1 (en)	2006-05-11	Novel diaminopropane-based metal chelators as antiviral agents